Huinno Aim

Huinno Aim is a healthcare platform that develops an artificial intelligence-based clinical decision support system (CDSS) for analyzing biosignal data of critically ill patients. Founded in 2022 in Seongdong, South Korea, the company was established by its parent company, Huinno, a developer of AI-based cardiac health monitoring devices. Huinno Aim secured $3.06 million in a seed funding round on August 17, 2022, with investors including Huinno, AON Investment, FuturePlay, Shinhan Capital, and Yuhan.

The company's core technology focuses on the immediate analysis of patient vital signs such as oxygen saturation, respiration, and body temperature to diagnose and predict serious diseases. This enables medical staff to respond quickly to various situations that occur in critically ill patients, supporting real-time patient monitoring and enhancing clinical decision-making. Huinno Aim's business model is centered on providing this platform to hospitals and healthcare professionals, aiming to improve the efficiency of treatment planning and patient care. The system is designed to create a service value chain that benefits patients through improved outcomes, healthcare professionals by reducing decision-making time, and health insurance providers by potentially lowering medical costs. The company collaborates with partner hospitals to acquire large-scale, labeled bio-signal data to continuously improve its AI models.

Keywords: clinical decision support system, CDSS, AI healthcare, biosignal analysis, patient monitoring, critical care technology, predictive diagnostics, HealthTech, medical AI, vital sign monitoring, real-time analytics, prescriptive analytics, Internet of Medical Things, IoMT, clinical diagnosis, patient data management, arrhythmia detection, Seoul, South Korea